



UPSIDE BIOTECHNOLOGIES

Upside Biotechnologies Company Profile

Overview

Upside is developing technology that will enable the production of the most advanced and usable human skin replacement product. The technology stems from research by Professor Rod Dunbar and Dr Vaughan Feisst, Department of Biological Sciences, University of Auckland, New Zealand.

Upside aims to generate returns in the shortest possible time by progressing its product to become the gold-standard, treatment of choice for victims of severe burns. The product is eligible for FDA orphan drug and Regenerative Medicine Advanced Therapy (RMAT) designation, both of which confer financial, speed to market and market protection advantages.

The company has a simple and streamlined structure with both Board and CEO having proven track records and global experience in field of human life sciences.

The company, which was incorporated in November 2016, closed on USD 1.8 million (NZD 2.3 million) equity financing in March 2017. These funds are being used to progress **Error! Reference source not found.** (the working name for Upside's burn treatment product) to readiness for a phase 1 clinical trial. Upside has signed a Cooperative Research and Development Agreement with the US Army.

The company seeks, from new investors, USD 10 million (NZD 14 million) to progress and conclude phase 1 and phase 2 human clinical trials with maximum speed.

Speaker Profile

Dr Robert Feldman, Chief Executive Officer



Dr Feldman has an invaluable combination of business, medical and research experience spanning over two decades. A qualified medical practitioner, he obtained his medical degree in London, his PhD in the Netherlands, has worked at Harvard Medical School and held clinical and academic positions at Imperial College, London. Dr Feldman is a successful serial life science entrepreneur, having founded the UK vaccine company Microscience and antimicrobial company Vmax.

continued...



He later went on to become CEO of hepatitis C therapeutic company, RioTech before establishing the European operations for the New York based company Paramount Biosciences, LLC. As Entrepreneur in Residence for Imperial Innovations, London, Dr Feldman also co-founded the spin-out company, Indigix. In 2010, he moved to New Zealand as Executive Director of Pacific Channel and subsequently founded his own life science consulting company, Line 5. He is now the CEO of Upside Biotechnologies Ltd.

During his extensive and varied career, Dr Feldman has developed a breadth of medical, research and commercial expertise encompassing therapeutics, devices, diagnostics. He has also gained a deep understanding of business and product development, fundraising, venture and governance. During Dr Feldman's time in the UK and New Zealand, he has engaged in business development activities globally, including concluding successful licensing deals in Europe, USA, Australia, Russia, South Korea and New Zealand.

For further information, please visit: upside.nz